Abstract:2934 Breast cancer presents as estrogen receptor alpha (ERα) positive or negative. ERα- tumors have a poor prognosis, are resistant to hormonal therapies, and frequently show overexpression, amplification, and/or hyperactivation of growth factor receptors, such as the erbB family. Using cell line models that mimic this elevated growth factor signaling by EGFR and erbB-2 in MCF-7 breast cancer cells, we have previously shown that hyperactivation of downstream p42/44 MAPK results in the reversible loss of ERα expression, and that in addition to the direct effect of MAPK on ERα, indirect activation of NFkB by MAPK also plays a role. In this study, we set out to determine if the inihibition of MAPK activity in established ERα- breast cancer cell lines could restore ERα expression and further, if this re-expressed ERα could now restore anti-estrogen response. MAPK inhibition via treatment with U0126 in 3 ERα- breast cancer cell lines, the EGFR overexpressing SUM 229s, the EGFR/c-erbB-2 dual overexperssing SUM 190s, and the RhoC overexpressing SUM 149s resulted in the sustained re-expression of ERα protein in all 3 cell lines. To ascertain that this re-expressed ERα could now restore anti-estrogen sensitivity, growth assays analyzing the effects of 4-hydroxy-tamoxifen (4HT) and the pure antiestrogen ICI 182,780 (faslodex) at 10-7 M alone, 5 μM U0126 alone, or the combination of 4HT or ICI and U0126 on cell proliferation were performed by WST-1 assay. ERα- SUM 229 and 149 cells were resistant to both 4HT and ICI. While having no growth inhibitory effects on its own, 5 μM U016 restored the growth inhibitory effects of both 4HT and ICI in ERα- SUM 229 cells, but not in SUM 149 cells. To determine if these in vitro cell line results would extrapolate to a real breast tumor situation, ERα- tumor specimens were obtained from the Tissue Procurement Core. Tumors were minced and divided evenly into a baseline sample and into tissue culture dishes containing medium alone, or supplemented with 10 μM U0126 or vehicle control DMSO. The minced tumor specimens in medium plus or minus U0126 were incubated at 37oC/5%CO2 for 20 hours. RNA was prepared from all treatment groups and analyzed for ERα mRNA level by qRT-PCR. Of the 12 tumors received to date, 6 displayed increased ERα mRNA levels after treatment with U0126. Collectively, these data are supportive of our hypothesis that there exists a population of ERα- tumors where upregulated growth factor signaling is directly involved in the generation of the ERα- phenotype by repressing ERα expression. Importanly, these data suggest that this reversible downregulation may be targeted clinically such that this repression can be reversed by inhibiting signaling through MAPK, resulting in re-expression of ERα and perhaps restoration of tamoxifen sensitivity.

ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells

Muscarinic Receptor-Mediated Activation of P70 S6 Kinase 1 (s6k1) in 1321n1 Astrocytoma Cells: Permissive Role of Phosphoinositide 3-Kinase

Muscarinic Receptors Mediate Phospholipase C-dependent Activation of Protein Kinase B Via Ca2+, ErbB3, and Phosphoinositide 3-Kinase in 1321N1 Astrocytoma Cells.

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

Caveolin-1 Down-Regulation Activates Estrogen Receptor Alpha Expression and Leads to 17 Beta-Estradiol-Stimulated Mammary Tumorigenesis

Altered MAP Kinase (ERK1,2) Regulation in Primary Cultures of Mammary Tumor Cells: Elevated Basal Activity and Sustained Response to EGF.

A CalDAG-GEFI/Rap1/B-Raf Cassette Couples M1Muscarinic Acetylcholine Receptors to the Activation of ERK1/2

Sphingosine Kinase Transmits Estrogen Signaling in Human Breast Cancer Cells.

C-Src Regulates Cell Cycle Proteins Expression Through Protein Kinase B/glycogen Synthase Kinase 3 Beta and Extracellular Signal-Regulated Kinases 1/2 Pathways in MCF-7 Cells

Estrogen Receptor Α Mediates Proliferation of Breast Cancer MCF–7 Cells Via a P21/pcna/e2f1‐dependent Pathway

Protein Kinase C ζ Is Required for Epidermal Growth Factor–Induced Chemotaxis of Human Breast Cancer Cells

Possible role of duration of PKC-induced ERK activation in the effects of agonists and phorbol esters on DNA synthesis in Panc-1 cells

Activation of G-protein coupled estrogen receptor inhibits the proliferation of cervical cancer cells via sustained activation of ERK1/2.

Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway.

Sphingosine Kinase (sphk) Mediates Transactivation of the Epidermal Growth Factor Receptor (egfr) by Estrogen in Breast Cancer Cells

Stabilization of MORC2 by Estrogen and Antiestrogens Through GPER1-PRKACA-CMA Pathway Contributes to Estrogen-Induced Proliferation and Endocrine Resistance of Breast Cancer Cells

Protein Kinase C Zeta is Required for Epidermal Growth Factor-Induced Chemotaxis of Human Breast Cancer Cells.

[Effects of Extracellular Signal-Regulated Kinase/mitogen-Activated Protein Kinase Signaling Pathway Activation on Proliferation and Cell Cycle Associated Genes in Human Colon Cancer Cells].

Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals

CREB Activity is Required for Epidermal Growth Factor‐induced Mouse Cumulus Expansion

Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells